Sydney Rosen
Profiles

Sydney B. Rosen, MPA

Research Professor, Global Health - Boston University School of Public Health

617-358-2251
sbrosen@bu.edu
Crosstown Center - 380
View Full Profile at BUMC

Biography

Sydney Rosen, M.P.A., is a Research Professor in the Department of Global Health at the Boston University School of Public Health and a Co-Director of the Health Economics and Epidemiology Research Office (HE2RO) of the University of the Witwatersrand in Johannesburg, South Africa. Her research addresses the economic consequences of the HIV/AIDS epidemic, and in particular the outcomes, costs, cost-effectiveness, and benefits of HIV and TB care and treatment interventions and models of service delivery. She is the principal investigator of multiple USAID-, NIH-, and foundation-supported studies and evaluations in South Africa and has worked extensively in Zambia, Malawi, and Kenya. She is also the author of policy and review papers on the business response to AIDS, the rationing of antiretroviral therapy, and the retention of patients in HIV/AIDS care and treatment programs. Her current projects include AMBIT, EVIDENCE, and EQUIP, all described on the BUSPH website. Professor Rosen’s technical training is in policy analysis and applied economics. She holds a BA magna cum laude from Harvard University and an MPA from the Kennedy School of Government at Harvard.

Other Positions

  • Co-Division Head, Health Economics and Epidemiology Research Office - University of the Witwatersrand

Education

  • Harvard University, MPA Field of Study: Economics
  • Harvard University, AB Field of Study: History

Websites

Publications

  • Published on 3/14/2023

    Jo Y, Jamieson L, Phiri B, Grimsrud A, Mwansa M, Shakwelele H, Haimbe P, Mukumbwa-Mwenechanya M, Mulenga PL, Nichols BE, Rosen S. Attrition from HIV treatment after enrollment in a differentiated service delivery model: A cohort analysis of routine care in Zambia. PLoS One. 2023; 18(3):e0280748. PMID: 36917568.

     Read At: PubMed
  • Published on 12/22/2022

    Jamieson L, Rosen S, Phiri B, Grimsrud A, Mwansa M, Shakwelele H, Haimbe P, Mukumbwa-Mwenechanya M, Lumano-Mulenga P, Chiboma I, Nichols BE. How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from a retrospective cohort study in Zambia. BMJ Open. 2022 Dec 22; 12(12):e064070. PMID: 36549722.

     Read At: PubMed
  • Published on 11/17/2022

    Antoniak S, Chasela CS, Freiman MJ, Stopolianska Y, Barnard T, Gandhi MM, Liulchuk M, Tsenilova Z, Viktor T, Dible J, Wose Kinge C, Akpan F, Minior T, Sigwebela N, Mohamed S, Barralon M, Marange F, Cavenaugh C, Horst CV, Antonyak S, Xulu T, Chew KW, Sanne I, Rosen S. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine. JGH Open. 2022 Dec; 6(12):894-903. PMID: 36514496.

     Read At: PubMed
  • Published on 11/3/2022

    Guthrie T, Muheki C, Rosen S, Kanoowe S, Lagony S, Greener R, Miot J, Balidawa H, Kiggundu J, Calnan J, Dejene S, Xulu T, Sigwebela N, Long LC. Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda. BMC Health Serv Res. 2022 Nov 03; 22(1):1315. PMID: 36329450.

     Read At: PubMed
  • Published on 10/11/2022

    Benade M, Long LC, Meyer-Rath G, Miot J, Evans D, Tucker JM, Moultrie H, Rosen S. Reduction in initiations of tuberculosis treatment in South Africa during the COVID pandemic. PLOS Global Public Health. 2022; 2(10):e0000559.

     Read At: Custom
  • Published on 10/11/2022

    Benade M, Long L, Meyer-Rath G, Miot J, Evans D, Tucker JM, Moultrie H, Rosen S. Reduction in initiations of drug-sensitive tuberculosis treatment in South Africa during the COVID-19 pandemic: Analysis of retrospective, facility-level data. PLOS Glob Public Health. 2022; 2(10):e0000559. PMID: 36962535.

     Read At: PubMed
  • Published on 10/11/2022

    Benade M, Long L, Meyer-Rath G, Miot J, Evans D, Tucker JM, Moultrie H, Rosen S. Reduction in initiations of drug-sensitive tuberculosis treatment in South Africa during the COVID-19 pandemic: Analysis of retrospective, facility-level data. PLOS Glob Public Health. 2022; 2(10):e0000559. PMID: 36962535.

     Read At: PubMed
  • Published on 7/27/2022

    Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. BMC Infect Dis. 2022 Jul 27; 22(1):650. PMID: 35896987.

     Read At: PubMed
  • Published on 3/31/2022

    Benade M, Long L, Rosen S, Meyer-Rath G, Tucker JM, Miot J. Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. BMC Health Serv Res. 2022 Mar 31; 22(1):428. PMID: 35361209.

     Read At: PubMed
  • Published on 12/8/2021

    Rosen S, Nichols B, Guthrie T, Benade M, Kuchukhidze S, Long L. Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. Gates Open Res. 2021; 5:177. PMID: 35310814.

     Read At: PubMed

View 137 more publications:View Full Profile at BUMC

News & In the Media

View all profiles